Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Alessio CirilloDaniele MarinelliUmberto RomeoDaniela MessineoFrancesca De FeliceMarco De VincentiisValentino ValentiniSilvia MeziFilippo ValentiniLuca VivonaAntonella ChiavassaBruna CerbelliDaniele SantiniPaolo BossiAntonella PolimeniPaolo MarchettiAndrea BotticelliPublished in: BMC cancer (2024)
PFS in our real-world cohort was similar to the KEYNOTE-048 reference while OS was numerically inferior. A deeper understanding of clinical variables that might affect survival outcomes of patients with R/M HNSCC beyond ECOG PS and PD-L1 CPS is urgently needed.